|
Aug 14
|
Zealand Pharma Announces Financial Results for the First Half of 2025
|
|
Aug 7
|
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
|
|
Jul 18
|
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
|
|
Jun 18
|
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
|
|
Apr 8
|
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
|
|
Feb 13
|
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
|
|
Oct 11
|
Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
|
|
Oct 9
|
FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants
|
|
Oct 8
|
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
|
|
Oct 8
|
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
|
|
Aug 30
|
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
|
|
Aug 28
|
Denmark’s Top Pension Fund Buys Weight-Loss Stocks After Run-Up
|
|
Aug 25
|
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
|
|
Jul 30
|
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
|
|
Jul 29
|
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
|
|
Jun 24
|
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
|
|
Jun 21
|
Existing home sales, a day with Fed's Susan Collins: Catalysts
|
|
Jun 21
|
Zealand Pharma's Weight Loss Drug Performs Well in Early Trials
|
|
Jun 21
|
Zealand Pharma surges on weight-loss drug trial results
|
|
Jun 21
|
Zealand Pharma says weight loss drug could be comparable to GLP1-RAs
|